A Re-evaluation and Validation of Ontogeny Functions for Cytochrome P450 1A2 and 3A4 Based on In Vivo Data
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background and ObjectivesCurrent cytochrome P450 (CYP) 1A2 and 3A4 ontogeny profiles, which are derived mainly from in vitro studies and incorporated in paediatric physiologically based pharmacokinetic models, have been reported to under-predict the in vivo clearances of some model substrates in neonates and infants.MethodWe report ontogeny functions for these enzymes as paediatric to adult relative intrinsic clearance per mg of hepatic microsomal protein, based on the deconvolution of in vivo pharmacokinetic data and by accounting for the impact of known clinical condition on hepatic unbound intrinsic clearance for caffeine and theophylline as markers of CYP1A2 activity and for midazolam as a marker of CYP3A4 activity.ResultsThe function for CYP1A2 describes an increase in relative intrinsic metabolic clearance from birth to 3 years followed by a decrease to adult values. The function for CYP3A4 describes a continuous rise in relative intrinsic metabolic clearance, reaching the adult value at about 1.3 years of age. The new models were validated by showing improved predictions of the systemic clearances of ropivacaine (major CYP1A2 substrate; minor CYP3A4 substrate) and alfentanil (major CYP3A4 substrate) compared with those using a previous ontogeny function based on in vitro data (alfentanil: mean squared prediction error 3.0 vs. 6.8; ropivacaine: mean squared prediction error 2.3 vs.14.2).ConclusionsWhen implementing enzyme ontogeny functions, it is important to consider potential confounding factors (e.g. disease) that may affect the physiological conditions of the patient and, hence, the prediction of net in vivo clearance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785 · cited 1×
“CYP1A2 is primarily responsible for the metabolism of caffeine and theophylline [13, 14] and metabolism by CYP3A4 is the main determinant of midazolam clearance [15].”
BackgroundJohnson, T. N., Rostami-Hodjegan, A., & Tucker, G. T. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645090-00005 · Cited by 530 · cited 10×
“In the absence of definitive information, it was assumed that the ontogenies of CYP3A4 and CYP3A5 are similar [4].”
BackgroundMethodInfluentialSelf-citationComparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7
Williams, J. A., Ring, B. J., Cantrell, V. E., Jones, D. R., Eckstein, J., Ruterbories, K., Hamman, M. A., Hall, S. D., & Wrighton, S. A. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.8.883 · Cited by 471 · cited 1×
“Only 10–25 % of Caucasians express CYP3A5, and the contribution of CYP3A7 to the metabolism of midazolam is relatively minor [44].”
BackgroundThe effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients.
Ulldemolins, M., Roberts, J. A., Rello, J., Paterson, D. L., & Lipman, J. (2011) · Clinical Pharmacokinetics · doi:10.2165/11539220-000000000-00000 · Cited by 469 · cited 1×
“ill children [31–33].”
Kamimori, G. H., Karyekar, C. S., Otterstetter, R., Cox, D. S., Balkin, T. J., Belenky, G. L., & Eddington, N. D. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(01)00958-9 · Cited by 449 · cited 1×
“[3] 84 18 to 35 76 166 84 76 146 84 76 130”
The utility of modeling and simulation in drug development and regulatory review
Huang, S.-M., Abernethy, D. R., Wang, Y., Zhao, P., & Zineh, I. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23570 · Cited by 206 · cited 1×
“paediatric drug development [1–3], uncertainties remain”
Maturation of caffeine elimination in infancy
Aranda, J. V., Collinge, J. M., Zinman, R., & Watters, G. (1979) · Archives of Disease in Childhood · doi:10.1136/adc.54.12.946 · Cited by 148 · cited 1×
“[58] 2 1 to 2.”
Midazolam as an Induction Agent in Children: A Pharmacokinetic and Clinical Study
Salonen, M., Kanto, J., lisalo, E., & Himberg, J.-J. (1987) · Anesthesia & Analgesia · doi:10.1213/00000539-198707000-00007 · Cited by 57
Cited by
Shebley, M., Sandhu, P., Emami Riedmaier, A., Jamei, M., Narayanan, R., Patel, A., Peters, S. A., Reddy, V. P., Zheng, M., de Zwart, L., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1013 · Cited by 395
“For some processes, such as maturation of drug-metabolizing enzymes, agerelated data are available and applied in pediatric models.(23,43) A recent example of a medium-impact application was deflazacort (Emflaza), for which a PBPK model was used in a regulatory submission to support dose adjustments when coadministere…”
MethodEFSA Scientific Committee, Hardy, A., Benford, D., Halldorsson, T., Jeger, M. J., Knutsen, H. K., More, S., Naegeli, H., Noteborn, H., Ockleford, C., et al. (2017) · EFSA Journal · doi:10.2903/j.efsa.2017.4849 · Cited by 202
“In 70% of cases, the predicted median clearances in neonates were within two-fold of the observed values (Johnson et al., 2006; Salem et al., 2014).”
BackgroundLin, W., Chen, Y., Unadkat, J. D., Zhang, X., Wu, D., & Heimbach, T. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03274-2 · Cited by 137
Reverse Translation in PBPK and QSP: Going Backwards in Order to Go Forward With Confidence
Rostami‐Hodjegan, A. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.904 · Cited by 90
Self-citationSmits, A., Annaert, P., Cavallaro, G., De Cock, P. A. J. G., de Wildt, S. N., Kindblom, J. M., Lagler, F. B., Moreno, C., Pokorna, P., Schreuder, M. F., et al. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14958 · Cited by 55
“In vivo data display additional variability.(45) For the CYP3A family, protein expression is 65–80% in foetuses but remains relatively constant at later ages.”
Background
Metadata
- Authors
- Salem, F., Johnson, T. N., Abduljalil, K., Tucker, G. T., & Rostami-Hodjegan, A.
- Venue
- Clinical Pharmacokinetics
- Published
- 2014-03-27
- Volume
- 53
- Issue
- 7
- Pages
- 625-636
- ISSN
- 0312-5963 (ISSN-L)
- 1179-1926
- OpenAlex
- W1970036717
- Cited by
- 128
- References
- 8
- FWCI
- 8.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Re-evaluation and Validation of Ontogeny Functions for Cytochrome P450 1A2 and 3A4 Based on In Vivo Data. https://app.cochat.ai/papers/10.1007/s40262-014-0140-7
- The paper
- Salem, F., Johnson, T. N., Abduljalil, K., Tucker, G. T., & Rostami-Hodjegan, A. (2014). A Re-evaluation and Validation of Ontogeny Functions for Cytochrome P450 1A2 and 3A4 Based on In Vivo Data. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-014-0140-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.